Literature DB >> 9084680

Generation and use of recombinant human bone sialoprotein and osteopontin for hydroxyapatite studies.

J T Stubbs1.   

Abstract

Bone sialoprotein (BSP) and osteopontin (OPN) are two extracellular bone matrix proteins that have the ability to modulate the growth of hydroxyapatite in vitro. Studies of BSP/OPN hydroxyapatite interactions in the past have been directed toward the identification of essential structural elements that allow these two proteins to modulate hydroxyapatite growth. However, these studies are limited by the finite quantities of purified extracellular matrix proteins. I have utilized a recombinant E. coli expression system to obtain milligram quantities of human bone sialoprotein and human osteopontin that may be used to study extracellular matrix protein interactions with hydroxyapatite.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9084680     DOI: 10.3109/03008209609029217

Source DB:  PubMed          Journal:  Connect Tissue Res        ISSN: 0300-8207            Impact factor:   3.417


  4 in total

1.  Isolation of a novel bone glycosylated phosphoprotein with disulphide cross-links to osteonectin.

Authors:  H Y Zhou; E Salih; M J Glimcher
Journal:  Biochem J       Date:  1998-03-15       Impact factor: 3.857

2.  A secretory system for bacterial production of high-profile protein targets.

Authors:  Alexander Kotzsch; Erik Vernet; Martin Hammarström; Jens Berthelsen; Johan Weigelt; Susanne Gräslund; Michael Sundström
Journal:  Protein Sci       Date:  2011-03       Impact factor: 6.725

Review 3.  Phosphorylated proteins and control over apatite nucleation, crystal growth, and inhibition.

Authors:  Anne George; Arthur Veis
Journal:  Chem Rev       Date:  2008-10-03       Impact factor: 60.622

4.  Separation Options for Phosphorylated Osteopontin from Transgenic Microalgae Chlamydomonas reinhardtii.

Authors:  Ayswarya Ravi; Shengchun Guo; Beth Rasala; Miller Tran; Stephen Mayfield; Zivko L Nikolov
Journal:  Int J Mol Sci       Date:  2018-02-16       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.